Breast Cancer Treatment in the Era of Precision Medicine

Breast Cancer Treatment in the Era of Precision Medicine

Blog Article

Breast cancer is the most common cancer in women in the Western world.Treatment decisions in the adjuvant and metastatic setting are based on three immunohistochemistry markers, namely estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).Based on the St.Gallen consensus, four distinct subtypes are defined: luminal A, luminal B, HER2-enriched and basal-like subtype breast grahams c+ eczema & dermatitis cream cancer.

In the era of precision medicine, more accurate profiling of breast cancer is now possible.Highly specific methods, including, but not limited to, next-generation sequencing (NGS), proteomics, and immune profiling, help to identify the targets for the appropriate treatment.Several international consortia trials, e.g.

, AURORA from the International Breast Cancer Study Group (IBCSG), pedaltrain pt 1 are on the way to standardize optimal molecular treatment for breast cancer patients.This review gives you a clinically oriented overview of treatments for all breast cancer subtypes and an insight into molecular techniques and profile-based decisions.It is an overview from clinicians for clinicians.